Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and NK Immunotherapy for Recurrent B-cell Lymphoma
NCT02843061Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HANK cells in B cell lymphoma, sponsored by Fuda Cancer Hospital. Primary endpoint: Relief degree evaluated by the RECIST at 3 months. Started Jul 2016; status: completed.
02
Drugs
HANK cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02843061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02843061.